Coghlan JG, Galiè N, Barberà JA, et al; AMBITION investigators. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension ...

Efficacy and Safety of Sotatercept in Patients With Pulmonary Arterial Hypertension (PAH) Associated With Connective Tissue ...

Scientists have created a new system to calculate the risk of short-term disease progression in people with pulmonary ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The classification of “responder” was earned by ...

A meta-analysis shows that clinical worsening is significantly less likely in patients with pulmonary arterial hypertension (PAH) if they are given combination treatment, rather than monotherapy.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Researchers reported a global PAH prevalence estimate of ...

The growth of the pulmonary arterial hypertension market is mainly driven by rising disease awareness, advances in targeted ...

With what Insmed calls an "outstanding" phase 2 win for its treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH), the company is racing to phase 3 as ...